# Simulations Plus, Inc. (SLP) — merger/definitive [pending]
Source: SEC API (secapi.ai) · situation sit_928f9feea0abc4a474e5 · retrieved 2026-08-11T15:54:05.381Z

## Overview
Simulations Plus, Inc. is a global leader and premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery and development, clinical trial operations, and commercialization.

Simulations Plus, Inc., a global provider of advanced software and consulting services for the biopharma sector, has agreed to be acquired by SP Evolution HoldCo II, LLC (Parent), an affiliate of Altaris, LLC, pursuant to an Agreement and Plan of Merger dated June 15, 2026. Under the merger agreement, SP Evolution BidCo II, LLC (Merger Sub) will merge with and into Simulations Plus, with Simulations Plus surviving as a wholly owned subsidiary of Parent. At the effective time of the merger, each outstanding share of Simulations Plus common stock will be converted into the right to receive $18.50 in cash per share, without interest, for a total transaction value of approximately $375,000,000. The merger consideration represents an approximately 26% premium to the volume-weighted average trading price for the 60-day trading period ended June 15, 2026. The Company's Board of Directors unanimously approved the Merger Agreement on June 15, 2026, and unanimously recommends that shareholders vote in favor of the merger. The merger is expected to close in the second half of 2026, subject to customary closing conditions including shareholder approval and required regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act.

## Terms
- Counterparty: SP Evolution HoldCo II, LLC (Altaris affiliate) · Deal value: $375.0M · Consideration: cash · Premium: 26.0% · Price/share: $18.5

## Key dates
- Announced 2026-07-22 · Record 2026-07-17 · Vote 2026-08-27

## Timeline
- 2026-07-22 · DEFM14A (0001023459-26-000051): DEFM14A - Simulations Plus, Inc. — *Simulations Plus, Inc. is a global leader and premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery and development, clinical trial operations, and commercialization.* Simulations Plus, Inc., a global provider of advanced software and consulting services for the biopharma sector, has agreed to be acquired by SP Evolution HoldCo II, LLC (Parent), an affiliate of Altaris, LLC, pursuant to an Agreement and Plan of Merger dated June 15, 2026. Under the merger agreement, SP Evolution BidCo II, LLC (Merger Sub) will merge with and into Simulations Plus, with Simulations Plus surviving as a wholly owned subsidiary of Parent. At the effective time of the merger, each outstanding share of Simulations Plus common stock will be converted into the right to receive $18.50 in cash per share, without interest, for a total transaction value of approximately $375,000,000. The merger consideration represents an approximately 26% premium to the volume-weighted average trading price for the 60-day trading period ended June 15, 2026. The Company's Board of Directors unanimously approved the Merger Agreement on June 15, 2026, and unanimously recommends that shareholders vote in favor of the merger. The merger is expected to close in the second half of 2026, subject to customary closing conditions including shareholder approval and required regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act.
  https://www.sec.gov/Archives/edgar/data/1023459/0001023459-26-000051.txt

## Citations
- 0001023459-26-000051 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000102345926000051